Neotron now able to detect nitrosamines in APIs and drugs
The European Medicines Agency (EMA) recently issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines. Nitrosamines are classified as probable human carcinogens and the EMA has asked manufacturers of medicines made with chemically synthesized active pharmaceutical ingredients (APIs) to test their products for the possible presence of such impurities.
In response to this crisis and in support of the pharmaceutical industry, Neotron Pharma GMP Lab, part of the Cotecna Group, has developed an effective analytical method which can detect nitrosamines in APIs and drugs.
To learn more, please download the full report published by Neotron, or contact customerservice.pharma@neotron.it
Latest News
03.05.2024
Zimbabwe Minister of Industry and Commerce visits Wimpey Lab and Cotecna UAE
The Zimbabwe Minister of Industry and Commerce Honourable Ndhlovu recently led a delegation visiting Cotecna and Wimpey Laboratories in the UAE.
01.05.2024
Cotecna participated in CESCO WEEK 2024
The CESCO WEEK 2024, one of the most important events in the mining industry in the world, took place from April 15-19 in Santiago Chile.